Please ensure Javascript is enabled for purposes of website accessibility

Why Endo International plc Is Crashing Today

By George Budwell - May 6, 2016 at 4:23PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Endo's shares are cratering after management slashes the drugmaker's 2016 annual guidance.

Source: Flickr via user Images Money.

What: Shares of Endo International plc (ENDP 9.75%) dropped by more than 40% today on roughly seven times the stock's normal volume. The drugmaker's stock is tumbling after management slashed the company's full year annual guidance for both total revenue (cut by 11% from its former high end estimate), and adjusted earnings per share (revised downwards by 23%). Endo's revised outlook stems from the loss of exclusivity for the anti-inflammatory medicine Voltaren Gel, as well as increasing competition in the generic drug space. 

So what: Endo's problems spilled over to its peers today, dragging down shares of nearly every company with a footprint in the generic-drug arena. For example, Allergan (AGN) saw its shares print new 52-week lows in the wake of this news, and Valeant Pharmaceuticals (BHC 3.23%) lost more than 13% of its value today, as well. 

AGN Chart

AGN data by YCharts.

Now what: The magnitude of these revisions seems to be the real problem. In a nutshell, analysts are questioning how management got it so wrong in the first place, and whether they even have a reliable estimate in place now. If not, Endo could continue to slide until the generic drug market finds a bottom.

Looking ahead, Allergan is set to release its earnings next week, which should provide additional insight into the generic drug space as a whole. Endo shareholders therefore may want to check out what Allergan's management has to say in its upcoming first-quarter conference call.

In the meantime, I think investors are best served by taking a wait-and-see approach with Endo. While this stock seems to offer strong value after this hefty sell-off, it's important to bear in mind that the market has shown little patience with pharma companies after Valeant's well-documented problems earlier this year.

In other words, the worst may be yet to come for Endo. Stay tuned.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Endo International plc Stock Quote
Endo International plc
ENDP
$0.40 (9.75%) $0.04
Allergan plc Stock Quote
Allergan plc
AGN
Bausch Health Companies Inc. Stock Quote
Bausch Health Companies Inc.
BHC
$9.58 (3.23%) $0.30

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
322%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.